Bluebird Bio, a US-based gene therapy specialist, plans to float on the Nasdaq stock exchange with a market capitalization of about $328m.
Bluebird plans to offer 5 million shares at between $14 and $16 each, with a further $750,000 shares available if demand is strong.
Investment banks JP Morgan and BoA Merrill Lynch are Bluebird’s lead underwriters for the initial public offering (IPO), with legal counsel from Goodwin Procter and Ropes & Gray.
Bluebird Bio posted a $6.5m net loss on…
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
